Piccioli Lucrezia, Arcopinto Michele, Salzano Andrea, D'Assante Roberta, Schiavo Alessandra, Stagnaro Francesca M, Lombardi Anna, Panicara Veronica, Valente Pietro, Vitale Giuseppe, Sarullo Filippo M, Giallauria Francesco, Marra Alberto M
Federico II University of Naples, Department of Translational Medical Sciences.
Monaldi Arch Chest Dis. 2018 Sep 5;88(3):975. doi: 10.4081/monaldi.2018.975.
Hormonal abnormalities are quite common in chronic heart failure (CHF). The most studied hormonal axis in CHF is the impairment of Growth Hormone (GH)/Insulin Growth Factor-1(IGF-1), which in turn is defined either by a blunted response to GH stimulation test or low serum IGF-1 values. Several independent groups reported that the presence of an abnormal GH/IGF-1 status in CHF is associated with a more severe disease, impaired functional capacity and reduced Survival rates. After the first encouraging results, double -blind controlled trials showed a neutral effect of the GH administration in patients. However, further studies reported positive results, when a GH-therapy is implemented only in those patients presenting a GH deficiency (replacement therapy).
激素异常在慢性心力衰竭（CHF）中相当常见。在CHF中研究最多的激素轴是生长激素（GH）/胰岛素样生长因子-1（IGF-1）受损，这反过来又通过对GH刺激试验反应迟钝或血清IGF-1值低来定义。几个独立的研究小组报告说，CHF中存在异常的GH/IGF-1状态与更严重的疾病、功能能力受损和生存率降低有关。在取得首批令人鼓舞的结果后，双盲对照试验显示给予GH对患者有中性作用。然而，进一步的研究报告了阳性结果，即仅对那些存在GH缺乏的患者实施GH治疗（替代疗法）时。
